AbCellera Biologics Inc (NAS:ABCL)

$ 2.995 0.045 (1.53%) Market Cap: 871.33 Mil Enterprise Value: 299.59 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 66/100

Q3 2024 Abcellera Biologics Inc Earnings Call Transcript
Nov 04, 2024

$2.89 (+5.86%)

Earnings
Q2 2024 Abcellera Biologics Inc Earnings Call Transcript
Aug 06, 2024

$2.85 (+3.26%)

Earnings
Q1 2024 Abcellera Biologics Inc Earnings Call Transcript
May 07, 2024

$4.04 (-1.70%)

Earnings
Q4 2023 Abcellera Biologics Inc Earnings Call Transcript
Feb 20, 2024

$5.31 (-0.56%)

Earnings
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Abcellera Biologics Inc Earnings Call Transcript
Nov 02, 2023

$4.43 (+7.52%)

Earnings
Q2 2023 Abcellera Biologics Inc Earnings Call Transcript
Aug 03, 2023

$6.97 (+0.43%)

Earnings
Abcellera Biologics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Abcellera Biologics Inc Earnings Call Transcript
May 04, 2023

$6.61 (+0.30%)

Earnings
Abcellera Biologics Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Q4 2022 Abcellera Biologics Inc Earnings Call Transcript
Feb 21, 2023

$8.89 (-7.30%)

Earnings
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Abcellera Biologics Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Q3 2022 Abcellera Biologics Inc Earnings Call Transcript
Nov 08, 2022

$12.24 (+1.92%)

Earnings
Q2 2022 Abcellera Biologics Inc Earnings Call Transcript
Aug 09, 2022

$11.11 (-5.53%)

Earnings
Q1 2022 Abcellera Biologics Inc Earnings Call Transcript
May 10, 2022

$6.64 (+2.15%)

Earnings
Abcellera Biologics Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022
Q4 2021 Abcellera Biologics Inc Earnings Call Transcript
Feb 24, 2022

$8.45 (+2.30%)

Earnings
Abcellera Biologics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
Q3 2021 Abcellera Biologics Inc Earnings Call Transcript
Nov 09, 2021

$14.71 (-4.04%)

Earnings
Abcellera Biologics Inc at Bank of America Tech Solutions for Drug Discovery Conference (Virtual) Transcript
Sep 20, 2021
Q2 2021 Abcellera Biologics Inc Earnings Call Transcript
Aug 12, 2021

$15.19 (-0.59%)

Earnings
Q1 2021 Abcellera Biologics Inc Earnings Call Transcript
May 13, 2021

$34.14 (+11.13%)

Earnings
Q4 2020 Abcellera Biologics Inc Earnings Call Transcript
Mar 29, 2021

Earnings

Q3 2022 Abcellera Biologics Inc Earnings Call Transcript

Nov 08, 2022 / 10:00PM GMT

Release Date Price: $12.24 (+1.92%)

Transcript 10-Q8-K

Operator

Good afternoon, and welcome to AbCellera's Third Quarter 2022 Business Update Conference Call. My name is Danielle, and I will facilitate the audio portion of today's interactive broadcast. (Operator Instructions) At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer.

Tryn T. Stimart

AbCellera Biologics Inc. - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Thank you. Good afternoon, and welcome to AbCellera's Third Quarter 2022 Business Update. We're pleased to have you with us today as we discuss the results announced in our press release issued just after the market closed today, which you can find on our Investor Relations website. With me on the call today are Dr. Carl Hansen, AbCellera's Chief Executive Officer and President; and Andrew Booth, AbCellera's Chief Financial Officer. The webcast portion of this call contains a slide presentation that we will refer to during the call. If you are following along on the phone and wish to access the slide portion of this

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.